- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| DIAGONAL BIO Aktie jetzt für 0€ handeln | |||||
| 25.04. | DIAGONAL BIO AB: Diagonal Bio announces change of news plattform | 1 | Cision News | ||
| 28.03. | DIAGONAL BIO AB: Diagonal Bio publishes Year-End Report for 2024 | 1 | Cision News | ||
| 21.03. | DIAGONAL BIO AB: Diagonal Bio granted patent in Japan | 1 | Cision News | ||
| 19.03. | Nomination Committee change in Diagonal Bio AB (publ.) | 1 | Cision News | ||
| 19.03. | DIAGONAL BIO AB: Trading in Diagonal Bio's shares and warrants of series TO 2 on NGM Nordic SME begins today | 1 | Cision News | ||
| 18.03. | NGM MARKET NOTICE: #25-27 Warrants issued by Diagonal Bio AB approved for listing at NGM | 2 | Cision News | ||
| 14.03. | NGM MARKET NOTICE: #25-23 Diagonal Bio AB approved for listing at NGM | 1 | Cision News | ||
| 13.03. | DIAGONAL BIO AB: Stall Courant and Diagonal Bio agree to a pilot test of LAMPlify® | 1 | Cision News | ||
| 04.03. | Diagonal Bio AB: Diagonal Bio has been approved for delisting from Nasdaq First North Growth Market | 249 | GlobeNewswire (Europe) | Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") today announces that Nasdaq has approved Diagonal Bio's application for delisting from Nasdaq First North Growth Market ("First North"). The... ► Artikel lesen | |
| 04.03. | Diagonal Bio AB: Diagonal Bio has received conditional approval for listing on NGM Nordic SME | 208 | GlobeNewswire (Europe) | Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") has received conditional approval for listing on NGM Nordic SME ("NGM"). The first day of trading is planned for 19 March 2025. This means that... ► Artikel lesen | |
| 07.02. | Diagonal Bio AB: Diagonal Bio AB's rights issue of units oversubscribed | 364 | GlobeNewswire (Europe) | The subscription period in Diagonal Bio AB's ("Diagonal Bio" or the "Company") rights issue of units of initially approximately SEK 6.0 million ended on 6 February 2025 (the "Rights Issue"). The Rights... ► Artikel lesen | |
| 29.01. | Diagonal Bio AB: Diagonal Bio announces positive pilot test results and secures order from StallZet | 132 | GlobeNewswire (Europe) | Diagonal Bio AB (publ) ("Diagonal Bio" or the "Company") announces an order valued at approximately SEK 150,000 from Daniel Redén, a renowned horse trainer at StallZet. The order comes as a result of... ► Artikel lesen | |
| 22.01. | Diagonal Bio AB: Diagonal Bio AB publishes investment memorandum prior to upcoming rights issue of units | 218 | GlobeNewswire (Europe) | The subscription period of Diagonal Bio AB's ("Diagonal Bio" or the "Company") rights issue of units, which was resolved on 23 December 2024 by the Board of Directors together with the resolution on... ► Artikel lesen | |
| 17.01. | XFRA CAPITAL ADJUSTMENT INFORMATION - 17.01.2025 | 812 | Xetra Newsboard | Das Instrument 2DV0 FR001400SVN0 DRONE VOLT SACA EO 1 EQUITY wird ex Kapitalmassnahme gehandelt am 17.01.2025 The instrument 2DV0 FR001400SVN0 DRONE VOLT SACA EO 1 EQUITY is traded ex capital adjustment... ► Artikel lesen | |
| 11.11.24 | Nasdaq Stockholm AB: Diagonal Bio AB receives observation status | 279 | GlobeNewswire | Today, on November 11, 2024, Diagonal Bio AB (the "Company") disclosed a press
release with information on the Company's financial situation.
The rules of Nasdaq First North Growth Market state that... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 10,260 | -0,29 % | Cathie Wood's ARK ETF adjusts portfolio, sells Roku stock, buys CRISPR and Intellia | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,085 | +0,41 % | PACB Partners With EpiCypher to Advance Epigenomics Using Fiber-Seq | ||
| CENTOGENE | 0,120 | +9,09 % | Research and Markets: Europe Hereditary Genetic Testing Market Research 2024-2033, Competitive Analysis of Centogene, Eurofins Scientific, and F. Hoffmann-La Roche - ResearchAndMarkets.com | The "Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 3,902 | +0,15 % | Deals im Milliarden-Markt für Psychedelika: AbbVie, Atai Life Sciences, Neural Therapeutics | ||
| BIOMERIEUX | 114,70 | -3,37 % | BIOMERIEUX: bioMérieux - First-Half 2025 Results | ||
| CYCLACEL | 6,129 | -4,53 % | Cyclacel Pharmaceuticals, Inc. - 8-K, Current Report | ||
| SYROS PHARMACEUTICALS | 0,108 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 25.03.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 25.03.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 25.03.2025.ISIN NameCA05553A1075 THE... ► Artikel lesen | |
| GENUS | 29,600 | 0,00 % | Genus - Additional Listing | ||
| ANAPTYSBIO | 18,700 | -0,53 % | AnaptysBio, Inc.: Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update | Announces positive data for rosnilimab, a pathogenic T cell depleter, through Week 38 from Phase 2b rheumatoid arthritis trialEnrollment completed for rosnilimab Phase 2 ulcerative colitis trial;... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 0,975 | -4,41 % | XTL Biopharmaceuticals Ltd.: XTL Names Mr. Noam Band as its New Chief Executive Officer | Brings a Wealth of Managerial Experience and Track Record RAMAT GAN, ISRAEL, April 07, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL") announced... ► Artikel lesen | |
| ABIONYX PHARMA | 3,640 | -1,09 % | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| AKESO | 15,100 | -9,58 % | Akeso, Inc.: Akeso Announces Completion of Patient Enrollment in Phase III Clinical Trial for Ivonescimab as First-Line Treatment for Biliary Tract Cancer Compared to PD-L1 Therapy | HONG KONG, Sept. 2, 2025 /PRNewswire/ -- Akeso (9926.HK) has recently announced the completion of patient enrollment in its Phase III, multicenter, randomized... ► Artikel lesen | |
| MEIRAGTX | 6,700 | +2,29 % | MeiraGTx Reports Second Quarter 2025 Financial and Operational Results | - Gained alignment with U.S. Food and Drug Administration (FDA) on the ongoing Phase 2 AQUAx2 randomized double-blind, placebo-controlled pivotal study in Grade 2/3 radiation-induced xerostomia (RIX)... ► Artikel lesen | |
| MAAT PHARMA | 3,930 | 0,00 % | MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology | Tranche-based financing to support clinical development for the Company's late-stage assets in hemato-oncology including Xervyteg currently under review for potential approval by the EMA and MaaT033... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,059 | -0,84 % | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-June 2025 | GOTHENBURG, Sweden, August 26, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January-June 2025 is now available, in Swedish, on the... ► Artikel lesen |
DIAGONAL BIO AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAGONAL BIO AB finden Sie auf Wallstreet Online.